Seed · Biotech · Copenhagen, Denmark · Founded 2021 · 6–10 employees
Alcolase is a Copenhagen-based biotech startup developing an enzyme-based technology that breaks down alcohol in the stomach before it enters the bloodstream, targeting the approximately 540 million people in East Asia living with ALDH2 deficiency — a genetic variant causing alcohol flush, nausea, and elevated health risks. Their proprietary liposomal encapsulation platform protects active enzymes from stomach acid, representing what the company calls the first enzyme system of its kind to survive the stomach's acidic environment. In May 2026, Alcolase closed a €1.5 million seed round led by Ada Ventures and Delphinus Venture Capital, with participation from Antler, Manigoff Invest, and business angels. The company plans to launch commercially in Singapore and South Korea, has early letters of intent from Asian pharmaceutical and food technology partners, and has established a UK therapeutic subsidiary to develop its enzyme delivery platform for broader clinical applications.
No open roles listed right now.